Compare · CMND vs NVO
CMND vs NVO
Side-by-side comparison of Clearmind Medicine Inc. (CMND) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMND and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 53311.3x CMND ($3.3M).
- Over the past year, CMND is down 99.8% and NVO is down 30.4% - NVO leads by 69.4 points.
- CMND has been more active in the news (8 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for CMND).
- Company
- Clearmind Medicine Inc.
- Novo Nordisk A/S
- Price
- $6.44-1.53%
- $38.82-1.05%
- Market cap
- $3.3M
- $173.66B
- 1M return
- -5.01%
- -10.14%
- 1Y return
- -99.80%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CMND
- SEC Form 6-K filed by Clearmind Medicine Inc.
- SEC Form 6-K filed by Clearmind Medicine Inc.
- Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
- SEC Form 6-K filed by Clearmind Medicine Inc.
- Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
- SEC Form 6-K filed by Clearmind Medicine Inc.
- Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
- SEC Form 6-K filed by Clearmind Medicine Inc.
- SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
- SEC Form 6-K filed by Clearmind Medicine Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank